Market Overview Preterm Birth and PROM Testing Market
The global preterm birth and prom testing market was valued at USD 1.5 billion in 2023 and is expected to reach USD 2.93 billion by 2032, growing at a CAGR of 7.7% during the forecast period. The market is witnessing strong momentum due to rising rates of preterm births, which currently affect approximately 15 million infants annually, according to the World Health Organization. Increasing awareness among healthcare providers, coupled with technological innovations and improved prenatal care, is accelerating the adoption of preterm birth and PROM testing solutions worldwide.
This report provides insights into the latest market trends, regional dynamics, adoption patterns, healthcare spending, and technological developments that are shaping the growth of the preterm birth and PROM testing market.
Explore Market Dynamics: Request Your Sample Report Now: https://www.snsinsider.com/sample-request/5890
Technological Advancements Driving Market Growth
Innovations in diagnostic tools are revolutionizing prenatal care. Blood-based predictive tests, such as PreTRM, measure specific protein levels to identify the risk of preterm birth between the 18th and 21st weeks of gestation. Such tests allow early intervention, reducing maternal and neonatal complications.
AI integration into prenatal diagnostics is another key growth driver. Machine learning models like Support Vector Machines (SVMs) can analyze complex patterns in patient data to predict preterm birth risk with up to 82% accuracy, providing clinicians with critical insights before a clinical diagnosis.
Other notable advancements include the PartoSure test, which measures placental alpha microglobulin-1 (PAMG-1) to predict imminent preterm delivery with a 97.4% negative predictive value within seven days. Additionally, innovative sensors like the University of Queensland’s “nanoflower sensor” enable first-trimester detection of pregnancy complications with over 90% accuracy.
Market Drivers
- Rising Incidence of Preterm Births: Globally, preterm birth rates are increasing, prompting greater demand for early diagnostic tools.
- Technological Innovations: Biomarker-based tests, AI-assisted imaging, and advanced point-of-care diagnostics improve early detection and clinical decision-making.
- Preventive Healthcare Focus: Improved prenatal monitoring and early interventions reduce neonatal ICU admissions and complications.
Market Restraints
High costs of advanced diagnostics and a shortage of trained healthcare professionals limit accessibility, especially in low-resource regions. Reports by the Comptroller and Auditor General highlight shortages of doctors (22%), nurses (35%), and paramedical staff (29%) in primary and secondary healthcare, impacting proper administration and interpretation of tests. These challenges hinder timely detection and intervention for preterm birth and PROM, affecting maternal and neonatal health outcomes.
Market Opportunities
The demand for point-of-care diagnostics and home testing kits offers a significant growth opportunity. New blood tests and sensor technologies allow early risk detection with high accuracy, enabling preventive care. Adoption of these tools can reduce preterm birth rates, optimize clinical outcomes, and expand access to prenatal testing in remote and underserved regions.
Market Challenges
Regulatory complexities are a critical barrier to market expansion. Many advanced diagnostics, such as PreTRM, lack FDA approval, slowing widespread adoption. Regulatory pathways are lengthy, involving extensive clinical trials to establish safety and efficacy. Differences in approval requirements across countries further complicate market entry. Collaboration between diagnostic companies and regulatory agencies is essential to streamline approvals while maintaining patient safety.
Market Segmentation Analysis
By Test Type:
- Ultrasound: In 2023, ultrasound accounted for 32% of the global market. Non-invasive and widely available, it enables evaluation of fetal development and cervical changes. 3D and 4D ultrasound advancements have further improved preterm birth risk prediction.
By Application:
- Preterm Labor: Represented 41% of the market in 2023 due to the high prevalence of preterm births globally.
- PROM: Though affecting only 3% of pregnancies, PROM accounts for 30-40% of preterm deliveries, driving adoption of biomarker-based diagnostic tests.
Regional Insights
- North America: Dominates with 38% market share in 2023 due to mature healthcare infrastructure, high maternal and neonatal care spending, and strong R&D investments. The U.S. increased preterm birth rates to 10.5% in 2021, prompting further research funding of over USD 500 million by NIH in 2022.
- Asia-Pacific: Expected to exhibit the fastest CAGR, driven by large populations, improving healthcare infrastructure, and government initiatives in India and China. Over 60% of preterm births occur in Africa and South Asia, highlighting substantial growth potential.
Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends: https://www.snsinsider.com/reports/preterm-birth-and-prom-testing-market-5890
Key Players
Hologic, Inc., Abbott Laboratories, Sera Prognostics Inc., CooperSurgical Inc., IQ Products, Qiagen N.V., Biosynex, LifeCell International Pvt. Ltd., Clinical Innovations, LLC, NX Prenatal, Inc., Medixbiochemica, Medtronic, Fisher & Paykel Healthcare Limited, FUJIFILM Holdings Corporation, Nonin Medical, Inc., Getinge AB, General Electric Company, Koninklijke Philips N.V., Promega Corporation, Medical Predictive Science Corporation
Recent Developments
- September 2024: Qiagen N.V. received FDA approval for a biomarker-based test predicting spontaneous preterm birth risk.
- January 2025: Abbott Laboratories launched an AI-enabled ultrasound system for preterm birth risk assessment, improving early detection and intervention capabilities.
Future Outlook
The preterm birth and PROM testing market is poised for sustained growth driven by increasing global awareness, rising incidence of preterm births, and advancements in predictive diagnostics. Adoption of AI-assisted tools and biomarker testing will continue to improve prenatal care outcomes. Expansion into emerging markets, particularly Asia-Pacific, will provide significant growth opportunities, supported by government health initiatives and rising investments in maternal health programs.
Conclusion
The global preterm birth and PROM testing market is set for rapid growth, fueled by technological innovations, AI-driven diagnostics, and increasing prevalence of preterm births. Key market players are introducing advanced tools, including predictive blood tests and ultrasound solutions, enhancing early detection and improving maternal and neonatal outcomes. Despite challenges related to high costs, workforce shortages, and regulatory complexities, the market is expected to reach USD 2.93 billion by 2032, driven by point-of-care testing, home diagnostics, and expanding healthcare infrastructure across emerging economies.
Explore SNS Insider Related Ongoing Coverage on Healthcare Market Insights Domain:
Disposable Blood Pressure Cuffs Market
Frequently Asked Questions (FAQ)
Q1. What is the current market size of the preterm birth and PROM testing market?
A1. The market was valued at USD 1.5 billion in 2023 and is expected to reach USD 2.93 billion by 2032.
Q2. What are the main drivers of market growth?
A2. Key drivers include increasing preterm birth incidence, technological advancements in diagnostics, AI-based prenatal care, and rising demand for early intervention tools.
Q3. Which regions are witnessing the highest growth?
A3. North America currently leads the market, while Asia-Pacific is expected to witness the fastest growth due to improving healthcare infrastructure and rising prenatal care awareness.
Q4. What are the major challenges in this market?
A4. High cost of diagnostics, shortage of trained healthcare professionals, and complex regulatory approvals hinder widespread adoption.
Q5. Who are the leading players in the preterm birth and PROM testing market?
A5. Leading players include Hologic, Abbott Laboratories, Sera Prognostics Inc., CooperSurgical Inc., Qiagen N.V., and General Electric Company.
